Therapeutic Targeting of EZH2 and BET BRD4 in Pediatric Rhabdoid Tumor.
Sign Up to like & getrecommendations! Published in 2022 at "Molecular cancer therapeutics"
DOI: 10.1158/1535-7163.mct-21-0646
Abstract: Aberrant activity of the H3K27 modifiers EZH2 and BRD4 is an important oncogenic driver for atypical teratoid/rhabdoid tumor (AT/RT), and each is potentially a possible therapeutic target for treating AT/RT. We therefore determined whether targeting… read more here.
Keywords: cell; targeting ezh2; ezh2 brd4; rhabdoid tumor ... See more keywords